Track the HLS Therapeutics Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in Canada. Shares trade on CA CA, under the oversight of SEDI. Market capitalisation: €133.2m. The latest transaction was disclosed on 30 June 2026 (56 - Grant of rights). Among the most active insiders: Hanna, John Gordon. All data is free.
16
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
35Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 16,653 of 26,334 companies
43.6
score / 100
Value
50
Quality
37
FCF yld11%
Earn yld-9.2%
EV/EBITDA11.5x
ROE-16%
Gross mgn82%
Net mgn-22%
Debt/EBITDA3.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
4,000 shares@ CA$4.30100.0% of flowCommon SharesTSXSEDI:4736753
Ideal exit: 13 Mar 2027 (T+270)
16 of 16 declarations
About HLS Therapeutics Inc.
HLS Therapeutics Inc. is a Canadian pharmaceutical company focused on the development and commercialization of treatments for chronic diseases. It is listed on the Toronto Stock Exchange under the symbol HLS.